Table 2. Prospective studies on high-dose therapy and autotransplantation in PTCL as first-line therapy.
| Author | n | Age | Regimen | Response before Tx | Tx-rate | OS | Follow-up |
|---|---|---|---|---|---|---|---|
| Present study | 111 | 49 | Cy/TBI or BEAM | 62% CR 20% PR 18% PD | 68% | 44% (5-year) | 59 |
| Mercadal14 | 41 | 47 | BEAM/BEAC | 49% CR 10% PR 39% PD | 41% | 39% (4-year) | 38 |
| D́Amore12 | 160 | 57 | BEAM/BEAC | 51% CR 30% PR 16% PD | 72% | 51% (5-year) | 61 |
| Corradini13a | 62 | 43 | Mito/Mel or BEAM | 56% CR 16% PR 24% PD | 74% | 34/21%b (12-year) | 76 |
| Rodriguez15 | 26/14c | 44 | BEAM | 65% CR 12% PR 19% PD | 73% | 73% (3-year) | 35 |
Abbreviations: CR, complete remission; PD, progressive disease; PR, partial remission; OS, overall survival.
a
Combined analysis of two separate studies, which included ALK-positive ALCL.
b
OS for all patients and non-ALK-positive histology, respectively.
c
Only 14/26 patients in this study received autoSCT as upfront therapy. Analysis includes all patients.